Inovio Pharmaceuticals (INO) Shares Down 5.6%
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)’s share price traded down 5.6% during trading on Tuesday . The company traded as low as $4.22 and last traded at $4.25. 2,036,886 shares traded hands during mid-day trading, an increase of 61% from the average session volume of 1,267,421 shares. The stock had previously closed at $4.50.
A number of equities analysts have recently commented on the stock. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 28th. Zacks Investment Research lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. ValuEngine lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. BidaskClub lowered shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 27th. Finally, Royal Bank of Canada started coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They issued an “outperform” rating and a $11.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. Inovio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $19.16.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.15). The company had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. Inovio Pharmaceuticals’s revenue for the quarter was down 79.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. equities analysts expect that Inovio Pharmaceuticals, Inc. will post -1.12 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in INO. Virginia Retirement Systems ET AL purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $101,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter worth about $107,000. Neuberger Berman Group LLC purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $115,000. Engineers Gate Manager LP purchased a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth about $117,000. Finally, Emerald Advisers Inc. PA boosted its position in shares of Inovio Pharmaceuticals by 84.0% in the 3rd quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 9,280 shares in the last quarter. Institutional investors and hedge funds own 32.27% of the company’s stock.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.